Calidi Biotherapeutics, Inc.
CLDI
$0.19
$0.015.19%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 21.23% | 9.90% | -14.62% | -21.70% | 18.94% |
| Total Depreciation and Amortization | -0.94% | 4.91% | 3.30% | 0.25% | 0.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -55.56% |
| Total Other Non-Cash Items | -80.40% | 20.61% | -0.20% | -5.88% | 77.44% |
| Change in Net Operating Assets | -1,252.21% | -68.66% | 97.79% | -34.89% | -282.65% |
| Cash from Operations | -19.02% | 13.16% | 31.57% | -31.50% | -9.64% |
| Capital Expenditure | -7.41% | 52.63% | -714.29% | -40.00% | 16.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -192.59% | 52.63% | -714.29% | -40.00% | 16.67% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | 93.32% | -3.06% | 76.48% | -8,673.68% | -5.56% |
| Issuance of Common Stock | -91.99% | 202,966.67% | -99.97% | -26.06% | 264.85% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -103.19% | 4,840.00% | 73.42% | 40.04% | -129.03% |
| Cash from Financing | -96.41% | 2,121.32% | -105.78% | -38.14% | 116.77% |
| Foreign Exchange rate Adjustments | -- | -100.00% | -- | -- | 148.48% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -191.56% | 196.57% | -656.70% | -87.39% | 625.16% |